CrystalGenomics Obtains European Patent for Pancreatic Cancer Drug Candidate 'Ivaltinostat'

[Asia Economy Reporter Lee Gwan-joo] CrystalGenomics announced on the 7th that its anticancer drug candidate 'Ivaltinostat,' being developed for pancreatic cancer indications, has obtained a European patent. The patent is titled "Pharmaceutically Acceptable Salts of Alkylcarbamoyl Naphthalenyl Oxy Octenoyl Hydroxamic Acid or Its Derivatives and Their Manufacturing Methods."

This patent acquisition was simultaneously registered in 38 European countries through the European Patent Office (EPO). Major countries include Germany, France, the United Kingdom, Italy, Spain, and Switzerland. It signifies that while maintaining exclusive rights to Ivaltinostat, new salts have been introduced to improve the stability and productivity of the raw material itself.

Additionally, since salt patent registration requires clear description of efficacy and experimental data to prove it, Ivaltinostat can be considered to have met all these conditions.

A CrystalGenomics official stated, "Currently, the clinical trial of Ivaltinostat targeting pancreatic cancer in the United States is progressing smoothly, and we will take a more proactive approach to strengthening global intellectual property rights accordingly."